Please Wait.....
Report
Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia), By End Use (Hospitals, Clinics, Others), By Region & Competition, 2020-2030F
Market Report I 2025-04-11 I 182 Pages I TechSci Research
Global Ankylosing Spondylitis (AS) therapeutics market was valued at USD 5.10 billion in 2024 and is expected to witness robust growth during the forecast period, registering a compound annual growth rate (CAGR) of 7.45% through 2030.
Ankylosing spondylitis is a chronic, inflammatory autoimmune disorder that predominantly affects the spine, leading to persistent pain, stiffness, and reduced mobility. Classified within the group of spondyloarthritis disorders, AS can also involve peripheral joints and various organs. The market for AS therapeutics has experienced notable progress in recent years, fueled by advancements in clinical research, the introduction of novel treatment modalities, and increased global awareness of the disease.
AS is marked by inflammation of the sacroiliac joints, connecting the sacrum at the base of the spine to the pelvis. Over time, this inflammation can result in the fusion of spinal vertebrae, severely limiting spinal flexibility and altering posture. Typically manifesting in early adulthood, common symptoms include lower back pain and morning stiffness. Timely diagnosis and effective disease management are essential to enhancing patients' quality of life.
Ankylosing spondylitis is a global health concern, affecting millions of individuals worldwide. Prevalence rates vary by region and population, with genetic factors-particularly the HLA-B27 gene-playing a major role in disease development. The AS therapeutics market has expanded considerably in recent years due to earlier diagnoses, increased treatment accessibility, and the availability of advanced therapeutics.
Key Market Drivers
Rising Prevalence of Ankylosing Spondylitis
The increasing global incidence of ankylosing spondylitis is a primary driver of market growth. Although AS affects a relatively small proportion of the population-ranging from 0.1% to 1.4%-its impact is significant, particularly among males and individuals in their most productive working years, often beginning in their mid-20s.
This growing patient base is intensifying the demand for effective, long-term therapeutic solutions, creating ample opportunities for pharmaceutical manufacturers and healthcare providers. Traditionally underdiagnosed due to its insidious onset and nonspecific symptoms, AS is now being identified earlier thanks to heightened awareness and advancements in diagnostic imaging technologies.
The ability to diagnose AS in its early stages enables earlier intervention, which enhances long-term treatment adherence and drives sustained demand for therapeutic products.
Key Market Challenges
Limited Awareness and Delayed Diagnosis
One of the core challenges faced by the AS therapeutics market is the limited awareness among both healthcare professionals and the general public. Misdiagnosis or late diagnosis remains a common issue, often resulting in delayed treatment and worsened patient outcomes. Addressing this gap through education and awareness campaigns is vital to improving early detection and disease management.
Key Market Trends
Technological Advancements in Diagnosis and Treatment
Emerging technologies have significantly improved the diagnostic accuracy and management of ankylosing spondylitis. Imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) are now routinely employed to detect early signs of inflammation and structural damage in the spine and sacroiliac joints. These high-resolution tools facilitate early diagnosis, which is crucial for initiating timely treatment.
Additionally, the integration of artificial intelligence (AI) and machine learning in image analysis has enhanced diagnostic precision. AI-driven tools are capable of identifying subtle pathological changes that might be overlooked by human evaluators, further supporting early and accurate diagnosis.
On the treatment front, advancements in biotechnology have led to the development of biological therapies-targeted drugs that address the specific immune mechanisms driving AS-related inflammation. TNF inhibitors have significantly improved patient outcomes by alleviating pain, stiffness, and inflammation. Furthermore, the emergence of biosimilars-cost-effective alternatives to biologic drugs-has broadened patient access to these life-changing treatments, especially in cost-sensitive markets.
Key Market Players
- AbbVie, Inc.
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Eli Lilly and Company
- UCB, Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc
Report Scope:
In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Ankylosing Spondylitis Therapeutics Market, By Drug:
o Cosentyx
o Humira
o Simponi
o Remicade
o Enbrel
o Cimzia
- Ankylosing Spondylitis Therapeutics Market, By End Use:
o Hospitals
o Clinics
o Others
- Ankylosing Spondylitis Therapeutics Market, By Region:
o North America
United States
Canada
Mexico
o Europe
France
United Kingdom
Italy
Germany
Spain
o Asia-Pacific
China
India
Japan
Australia
South Korea
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.
Available Customizations:
Global Ankylosing Spondylitis Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Ankylosing Spondylitis Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia)
5.2.2. By End Use (Hospitals, Clinics, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Ankylosing Spondylitis Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Ankylosing Spondylitis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug
6.3.1.2.2. By End Use
6.3.2. Canada Ankylosing Spondylitis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug
6.3.2.2.2. By End Use
6.3.3. Mexico Ankylosing Spondylitis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug
6.3.3.2.2. By End Use
7. Europe Ankylosing Spondylitis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Ankylosing Spondylitis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug
7.3.1.2.2. By End Use
7.3.2. United Kingdom Ankylosing Spondylitis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug
7.3.2.2.2. By End Use
7.3.3. Italy Ankylosing Spondylitis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug
7.3.3.2.2. By End Use
7.3.4. France Ankylosing Spondylitis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug
7.3.4.2.2. By End Use
7.3.5. Spain Ankylosing Spondylitis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug
7.3.5.2.2. By End Use
8. Asia-Pacific Ankylosing Spondylitis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug
8.2.2. By End Use
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Ankylosing Spondylitis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug
8.3.1.2.2. By End Use
8.3.2. India Ankylosing Spondylitis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug
8.3.2.2.2. By End Use
8.3.3. Japan Ankylosing Spondylitis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug
8.3.3.2.2. By End Use
8.3.4. South Korea Ankylosing Spondylitis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug
8.3.4.2.2. By End Use
8.3.5. Australia Ankylosing Spondylitis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug
8.3.5.2.2. By End Use
9. South America Ankylosing Spondylitis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug
9.2.2. By End Use
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Ankylosing Spondylitis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug
9.3.1.2.2. By End Use
9.3.2. Argentina Ankylosing Spondylitis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug
9.3.2.2.2. By End Use
9.3.3. Colombia Ankylosing Spondylitis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug
9.3.3.2.2. By End Use
10. Middle East and Africa Ankylosing Spondylitis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug
10.2.2. By End Use
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Ankylosing Spondylitis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug
10.3.1.2.2. By End Use
10.3.2. Saudi Arabia Ankylosing Spondylitis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug
10.3.2.2.2. By End Use
10.3.3. UAE Ankylosing Spondylitis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug
10.3.3.2.2. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Ankylosing Spondylitis Therapeutics Market: SWOT Analysis
14. Competitive Landscape
14.1. AbbVie, Inc.
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Amgen, Inc.
14.3. Pfizer, Inc.
14.4. Novartis AG
14.5. Eli Lilly and Company
14.6. UCB, Inc.
14.7. Johnson & Johnson Services, Inc.
14.8. Merck & Co., Inc
15. Strategic Recommendations
16. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security